Oncolytics Biotech Inc. (ONCY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oncolytics Biotech Inc. (ONCY) trades at $0.8017 with AI Score 28/100 (Grade F). Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on the discovery and development of cancer treatments. Market cap: $80.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026ONCY stock analysis for 2026: Analysts have set a consensus price target of $5.52 for Oncolytics Biotech Inc., suggesting 589.0% upside from the current price of $0.80. The AI MoonshotScore is 28/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ONCY: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Oncolytics Biotech Inc. (ONCY) Healthcare & Pipeline Overview
Oncolytics Biotech Inc. is a development-stage biopharmaceutical company specializing in cancer therapeutics, primarily focused on its lead product, pelareorep, an intravenously delivered immunotherapeutic agent. The company collaborates with industry giants like Merck KGaA and Pfizer Inc. to advance its clinical programs in solid tumors and hematological malignancies.
What Is the Investment Thesis for ONCY?
Oncolytics Biotech Inc. presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The core value driver is the clinical progress of pelareorep, their lead immunotherapeutic agent. Positive data from ongoing and future clinical trials, particularly in combination with established therapies like paclitaxel and avelumab, could significantly increase the company's valuation. The co-development agreements with Merck KGaA and Pfizer Inc. provide validation of pelareorep's potential and offer financial support for clinical development. However, the company's development-stage status carries inherent risks, including clinical trial failures, regulatory hurdles, and the need for additional funding. The current market capitalization of $80.5M reflects both the potential upside and the significant risks associated with investing in a company with no approved products. Successful commercialization of pelareorep, or its out-licensing to a larger pharmaceutical company, would be key catalysts for value appreciation.
Based on FMP financials and quantitative analysis
ONCY Key Highlights
Lead product pelareorep targets solid tumors and hematological malignancies, offering a broad therapeutic potential.
- Co-development agreements with Merck KGaA and Pfizer Inc. validate the technology and provide financial support.
- Pelareorep acts as an immunotherapeutic agent, stimulating the body's immune system to fight cancer.
- Company is focused on clinical trials to evaluate the efficacy and safety of pelareorep in various cancer indications.
- Market capitalization of $80.5M reflects the development-stage nature and associated risks.
Who Are ONCY's Competitors?
ONCY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ONCY's Key Strengths?
Novel immunotherapeutic approach with pelareorep.
- Co-development agreements with major pharmaceutical companies.
- Targeting a large and growing market for cancer therapeutics.
- Experienced management team with expertise in drug development.
What Are ONCY's Weaknesses?
Development-stage company with no approved products.
- Reliance on a single lead product, pelareorep.
- High cash burn rate and need for additional funding.
- Intense competition in the biotechnology industry.
What Could Drive ONCY Stock Higher?
Data readouts from ongoing clinical trials of pelareorep in combination with other therapies.
- Potential regulatory submissions for pelareorep in specific cancer indications.
- Continued enrollment and progress in ongoing clinical trials.
- Expansion of partnerships with other pharmaceutical companies.
- Advancements in the development of earlier-stage pipeline programs.
What Are the Key Risks for ONCY?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or negative data readouts.
- Regulatory delays or rejection of marketing applications.
- Competition from other cancer therapies.
- Dependence on a single lead product, pelareorep.
- Need for additional funding to support clinical development.
What Are the Growth Opportunities for ONCY?
- Expansion of Pelareorep's Clinical Applications: Oncolytics has the opportunity to expand the clinical applications of pelareorep beyond its current focus on breast cancer. Exploring its efficacy in other solid tumors, such as lung cancer, ovarian cancer, and melanoma, could significantly broaden its market potential. The global market for cancer therapies is projected to reach $286 billion by 2028, offering a substantial opportunity for Oncolytics to capture a share of this market through successful clinical trials and regulatory approvals. Timeline: Ongoing clinical trials with potential data readouts in the next 2-3 years.
- Combination Therapies: Oncolytics can leverage its existing partnerships with Merck KGaA and Pfizer Inc. to develop novel combination therapies involving pelareorep and other anti-cancer agents. Combining pelareorep with checkpoint inhibitors or targeted therapies could enhance its efficacy and address a wider range of cancer patients. The market for combination cancer therapies is rapidly growing, driven by the increasing recognition of synergistic effects between different treatment modalities. Timeline: Ongoing and planned clinical trials over the next 3-5 years.
- Out-Licensing or Acquisition: Oncolytics could pursue out-licensing agreements or a potential acquisition by a larger pharmaceutical company. Positive clinical data and regulatory advancements could increase the attractiveness of pelareorep to potential partners or acquirers. The biotechnology industry is characterized by frequent mergers and acquisitions, providing an exit strategy for investors and an opportunity for Oncolytics to realize the value of its technology. Timeline: Potential for strategic transactions within the next 2-5 years.
- Advancement of Pipeline Programs: Oncolytics can focus on advancing its earlier-stage pipeline programs beyond pelareorep. Developing new immunotherapeutic agents or exploring novel targets in cancer biology could diversify its product portfolio and reduce its reliance on a single asset. The biotechnology industry rewards innovation and the development of differentiated technologies. Timeline: Preclinical and early-stage clinical development over the next 5-7 years.
- Personalized Medicine Approach: Oncolytics can explore a personalized medicine approach by identifying biomarkers that predict patient response to pelareorep. This would allow for more targeted treatment and improve clinical outcomes. The personalized medicine market is rapidly growing, driven by advancements in genomics and diagnostics. By tailoring its therapy to specific patient populations, Oncolytics can enhance its competitive advantage and increase its market share. Timeline: Ongoing research and development efforts with potential clinical applications in the next 3-5 years.
What Threats Does ONCY Face?
- Clinical trial failures or regulatory setbacks.
- Competition from other cancer therapies.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
What Are ONCY's Competitive Advantages?
- Proprietary Technology: Pelareorep is a unique immunotherapeutic agent with a specific mechanism of action.
- Clinical Data: Positive clinical data demonstrating the efficacy and safety of pelareorep.
- Strategic Partnerships: Co-development agreements with Merck KGaA and Pfizer Inc.
- Patent Protection: Intellectual property rights covering pelareorep and its applications.
What Does ONCY Do?
Oncolytics Biotech Inc., founded in 1998 and headquartered in Calgary, Canada, is a development-stage biopharmaceutical company dedicated to the discovery and development of innovative pharmaceutical products for the treatment of cancer. The company's primary focus is on its lead product, pelareorep, an intravenously delivered, non-pathogenic, proprietary isolate of the reovirus. Pelareorep is designed to selectively infect and lyse cancer cells that harbor an activated Ras pathway, a common characteristic in many types of solid tumors and hematological malignancies. Pelareorep acts as an immunotherapeutic agent, stimulating the body's own immune system to recognize and attack cancer cells. Oncolytics is actively pursuing clinical trials to evaluate the efficacy and safety of pelareorep in various cancer indications, both as a monotherapy and in combination with other anti-cancer agents. The company has established strategic co-development agreements with major pharmaceutical companies such as Merck KGaA and Pfizer Inc. to explore the potential of pelareorep in combination with other therapies, including avelumab, a human anti-PD-L1 antibody, for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. These collaborations underscore the potential of Oncolytics' technology and its commitment to advancing cancer care. Oncolytics is also working with PrECOG LLC to further investigate the therapeutic potential of pelareorep. With a team of 28 employees, Oncolytics Biotech Inc. continues to focus on advancing its clinical programs and expanding its pipeline of cancer therapeutics.
What Products and Services Does ONCY Offer?
- Develop pharmaceutical products for the treatment of cancer.
- Focus on immunotherapeutic agents.
- Conduct clinical trials to evaluate the efficacy and safety of their products.
- Collaborate with pharmaceutical companies for co-development agreements.
- Target solid tumors and hematological malignancies.
- Utilize pelareorep, an intravenously delivered agent, as their lead product.
How Does ONCY Make Money?
- Develop and commercialize cancer therapeutics.
- Generate revenue through product sales, licensing agreements, and collaborations.
- Invest in research and development to expand their product pipeline.
- Partner with larger pharmaceutical companies for clinical development and commercialization.
What Industry Does ONCY Operate In?
Oncolytics Biotech operates within the highly competitive biotechnology industry, specifically focusing on cancer therapeutics. The market for cancer treatments is substantial and growing, driven by an aging population and advancements in personalized medicine. The competitive landscape includes large pharmaceutical companies with established oncology portfolios, as well as numerous smaller biotech companies developing novel therapies. Oncolytics differentiates itself through its unique immunotherapeutic approach with pelareorep, which selectively targets cancer cells with an activated Ras pathway. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships to navigate the complex regulatory and commercialization pathways.
Who Are ONCY's Key Customers?
- Cancer patients suffering from solid tumors and hematological malignancies.
- Hospitals and oncology clinics that administer cancer treatments.
- Pharmaceutical companies seeking to collaborate on cancer therapeutics.
- Research institutions involved in cancer research and clinical trials.
Key Financial Metrics
Its free cash flow yield is -23.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.5%, the inverse of the P/E and a quick read on earnings relative to price.
Oncolytics Biotech Inc. (ONCY) Valuation Context
Valued at $80.5M, ONCY is classified as a micro-cap stock. Relative to its peer group, ONCY's quantitative score of 28/100 is below the peer average of 74/100.
Company Profile
Oncolytics Biotech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jared Kelly. ONCY has traded publicly since 2001.
Financial Health
Oncolytics Biotech Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Oncolytics Biotech Inc. revenue of about $1.2M for fiscal 2026, with EPS near $-0.35. The estimate reflects 5 contributing analysts.
ONCY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a belief in upcoming positive developments.
- Community sentiment has shifted positively, with increased discussions around potential breakthroughs in Oncolytics' therapies.
- Analysts have highlighted the promising results from recent clinical trials, enhancing the company's credibility in the biotech space.
- The growing interest in cancer therapies has bolstered market perception, positioning Oncolytics as a key player in an expanding sector.
Bear Case
- Concerns about funding and cash flow have emerged, raising questions about the company's ability to sustain operations without additional capital.
- Negative sentiment from some investors reflects skepticism about the timeline for regulatory approvals, which could impact growth.
- Recent market volatility has led to cautious trading behavior, with some community members expressing doubts about the stock's resilience.
- There are lingering uncertainties regarding competition in the biotech field, which may overshadow Oncolytics' potential advancements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ONCY Latest News
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Jul 9, 2026
ONCY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ONCY.
Price Targets
Consensus target: $5.52
ONCY MoonshotScore
What does this score mean?
The MoonshotScore rates ONCY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jared Kelly
CEO
Jared Kelly serves as the CEO of Oncolytics Biotech Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on corporate strategy, business development, and financial management. Prior to joining Oncolytics, Kelly held leadership positions at various life sciences companies, where he was responsible for driving growth, securing strategic partnerships, and overseeing financial operations. His expertise spans a range of therapeutic areas, including oncology, immunology, and infectious diseases. Kelly's educational background includes advanced degrees in business and science.
Track Record: Under Jared Kelly's leadership, Oncolytics Biotech Inc. has focused on advancing the clinical development of pelareorep, the company's lead immunotherapeutic agent. Key achievements include securing co-development agreements with Merck KGaA and Pfizer Inc. to explore pelareorep's potential in combination with other anti-cancer therapies. Kelly has also overseen the expansion of Oncolytics' clinical trial program and the strengthening of its intellectual property portfolio. His strategic decisions have positioned the company for potential future growth and success.
Oncolytics Biotech Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for ONCY?
ONCY holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on the discovery and development of cancer treatments. Their lead product, pelareorep, is an intravenously delivered …
What does Oncolytics Biotech Inc. do?
Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on discovering and developing pharmaceutical products for the treatment of cancer. Their lead product is pelareorep, an intravenously delivered immunotherapeutic agent designed to selectively infect and lyse cancer cells with an activated Ras pathway, a common characteristic in many types of solid tumors and hematological malignancies.
What do analysts say about ONCY stock?
Analyst coverage of Oncolytics Biotech Inc. (ONCY) is limited, reflecting its development-stage nature and relatively small market capitalization. However, analysts generally view the company's pelareorep technology as promising, particularly its potential in combination with other cancer therapies. Key valuation metrics are difficult to assess due to the lack of revenue-generating products.
What are the main risks for ONCY?
The main risks for Oncolytics Biotech Inc. (ONCY) are inherent to its development-stage status and the biotechnology industry. Clinical trial failures or negative data readouts pose a significant risk, as they could halt the development of pelareorep and negatively impact the company's valuation. Regulatory delays or rejection of marketing applications could also impede progress.
What are the key factors to evaluate for ONCY?
Oncolytics Biotech Inc. (ONCY) holds an AI score of 28/100 (low). Analysts target $5.52 (+589%). presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. Not financial advice.
How frequently does ONCY data refresh on this page?
ONCY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ONCY's recent stock price performance?
Oncolytics Biotech Inc. (ONCY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel immunotherapeutic approach with pelareorep. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ONCY overvalued or undervalued right now?
Oncolytics Biotech Inc. (ONCY) is loss-making, so its trailing P/E is negative (-2.4x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $5.52 (+589%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ONCY before investing?
Before investing in Oncolytics Biotech Inc. (ONCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.